Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049337 | PMC |
| http://dx.doi.org/10.3324/haematol.2019.219352 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of genetically proxied cancer-targeted drugs with cardiovascular diseases through Mendelian randomization analysis.
J Transl Med
January 2025
Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Background: Cancer-targeted therapies are progressively pivotal in oncological care. Observational studies underscore the emergence of cancer therapy-related cardiovascular toxicity (CTR-CVT), impacting patient outcomes. We aimed to investigate the causal relationship between different types of cancer-targeted therapies and cardiovascular disease (CVD) outcomes through a two-sample Mendelian randomization (MR) study.
View Article and Find Full Text PDFMyelodysplastic syndromes among atomic bomb survivors in Nagasaki: similarities to and differences from de novo and therapy-related cases.
J Radiat Res
December 2024
Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan.
Epidemiological studies for atomic bomb (A-bomb) survivors clearly demonstrated that A-bomb radiation increased the risk of hematological neoplasms, such as acute and chronic leukemia, and myelodysplastic syndromes (MDS) among survivors. Several studies on MDS among survivors investigated its characteristics, and it seems that MDS among survivors has different features from those seen in de novo MDS and therapy-related MDS. In this short review, we describe the differences of clinical features, chromosomal alterations and genome aberrations among them.
View Article and Find Full Text PDFGenetic and epigenetic bases of long-term adverse effects of childhood cancer therapy.
Nat Rev Cancer
November 2024
Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Over the past decade, genome-scale molecular profiling of large childhood cancer survivorship cohorts has led to unprecedented advances in our understanding of the genetic and epigenetic bases of therapy-related adverse health outcomes in this vulnerable population. To facilitate the integration of knowledge generated from these studies into formulating next-generation precision care for survivors of childhood cancer, we summarize key findings of genetic and epigenetic association studies of long-term therapy-related adverse effects including subsequent neoplasms and cardiomyopathies among others. We also discuss therapy-related genotoxicities including clonal haematopoiesis and DNA methylation, which may underlie accelerated molecular ageing.
View Article and Find Full Text PDFGenomic profiles and outcomes in de novo versus therapy-related core binding factor AML.
Blood Cancer J
October 2024
Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada.
Incorporating familial risk, lifestyle factors, and pharmacogenomic insights into personalized noncommunicable disease (NCD) reports for healthcare funder beneficiaries participating in the Open Genome Project.
Ann Hum Genet
October 2024
Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Introduction: An ethics-guided decision-making framework was developed for applying pathology-supported genetic testing, a multifaceted pharmacodiagnostic approach that translates population risk stratification into clinical utility. We introduce this service, supported by the Open Genome Project, which aligns with the beneficence principle in personalized medicine.
Methods: Genetic testing of six noncommunicable disease pathways was conducted as part of a pilot program, benchmarked against a readiness checklist for implementation of genomic medicine in Africa.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!